ChromaDex to Present at the 10th Annual LD Micro Main Event
November 29 2017 - 5:30AM
ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated
nutraceutical company devoted to extending human healthspan,
announced today that its Chief Executive Officer and Co-Founder,
Frank Jaksch will present at the 10th annual LD Micro Main Event at
the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
Mr. Jaksch is scheduled to present on Tuesday, December 5, 2017,
at 1:00 p.m. PST. ChromaDex management will also attend one-on-one
meetings with institutional investors throughout the day.
The LD Micro Main Event is the largest independent conference
for small/micro-cap companies and will feature 250 names presenting
to an audience of over 1,000 attendees. In addition, there will be
a variety of speakers/panelists discussing topics of interest to
investors and issuers.
About ChromaDex:
ChromaDex leverages its complementary business units to
discover, acquire, develop and commercialize patented and
proprietary health and wellness consumer products and ingredient
technologies that promote healthy longevity. In addition to our
consumer product and ingredient technologies units, we also have
business units focused on natural product fine chemicals (known as
"phytochemicals"), and product regulatory and safety consulting. As
a result of our relationships with leading universities and
research institutions, we are able to discover and license early
stage, IP-backed ingredient technologies. We then utilize our
in-house chemistry, regulatory and safety consulting business units
to develop commercially viable ingredients. Our consumer product
and ingredient portfolio are backed with clinical and scientific
research, as well as extensive IP protection. Our portfolio of
patented ingredient technologies
includes NIAGEN® nicotinamide
riboside; pTeroPure® pterostilbene; PURENERGY®, a
caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina
extract; and AnthOrigin®, anthocyanins derived from a
domestically-produced, water-extracted purple corn husk. To learn
more about ChromaDex, please visit www.ChromaDex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. Actual results may differ materially from those set
forth in this release due to the risks and uncertainties inherent
in ChromaDex's business. More detailed information about ChromaDex
and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2016,
ChromaDex's Quarter Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
ChromaDex Investor Relations Contact: Andrew
Johnson, Director of Investor Relations 949-419-0288
andrewj@chromadex.com
ChromaDex Public Relations Contact: Breah
Ostendorf, Director of Marketing 949-537-4103
breaho@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2024 to May 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From May 2023 to May 2024